Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.001,76
0,18%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Aclaris Therapeutics Inc (ACRS) Aclaris Therapeutics Inc (ACRS) Notizie

Aclaris Therapeutics Inc

ACRS
1,38
0,07 (5,34%)
04 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
30/4/202413:00GLOBEAclaris Therapeutics to Announce First Quarter 2024..
23/4/202414:00PRNUSFlare Therapeutics Appoints Douglas Manion, M.D., FRCP (C)..
05/3/202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202413:30EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/2/202413:14EDGAR2Form 8-K - Current report
27/2/202413:00GLOBEAclaris Therapeutics Reports Fourth Quarter and Full Year..
15/2/202402:32EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202420:06EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202420:24EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202401:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202422:31EDGAR2Form 8-K/A - Current report: [Amend]
05/2/202422:30EDGAR2Form 8-K - Current report
19/1/202413:30EDGAR2Form 8-K - Current report
16/1/202413:00GLOBEAclaris Therapeutics Announces Leadership Changes and..
10/1/202413:00GLOBEAclaris Therapeutics Announces Top-line Results from 4-Week..
03/1/202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202322:15EDGAR2Form 8-K - Current report
19/12/202322:01GLOBEAclaris Therapeutics Provides Corporate Update
05/12/202322:01GLOBEAclaris Therapeutics Announces Patent License Agreement with..
13/11/202313:42EDGAR2Form 8-K - Current report
13/11/202313:00GLOBEAclaris Therapeutics Announces Top-line Results from 12-Week..
06/11/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202313:15EDGAR2Form 8-K - Current report
06/11/202313:00GLOBEAclaris Therapeutics Reports Third Quarter 2023 Financial..
25/10/202322:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/10/202322:06EDGAR2Form 144 - Report of proposed sale of securities
03/10/202313:00GLOBEAclaris Therapeutics Completes Enrollment in Phase 2b Study..
20/9/202313:00GLOBEAclaris Therapeutics to Participate in the 2023 Cantor..
18/9/202314:00EDGAR2Form 8-K - Current report
18/9/202313:00GLOBEAclaris Therapeutics Announces Positive Results from Phase 1..
07/9/202322:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202323:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202322:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/8/202322:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/8/202322:20EDGAR2Form 144 - Report of proposed sale of securities
07/8/202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202313:15EDGAR2Form 8-K - Current report
07/8/202313:00GLOBEAclaris Therapeutics Reports Second Quarter 2023 Financial..
03/8/202322:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202322:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202313:01GLOBEAclaris Therapeutics Completes Enrollment in Phase 2b Study..
02/6/202313:00GLOBEAclaris Therapeutics to Participate in Two June Healthcare..
08/5/202313:00GLOBEAclaris Therapeutics Reports First Quarter 2023 Financial..
Apertura: 1,31 Min: 1,31 Max: 1,40
Chiusura: 1,31

La tua Cronologia

NASDAQ
ACRS
Aclaris Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network